{"id":"NCT01989676","sponsor":"Pfizer","briefTitle":"A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin速 [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-02-24","primaryCompletion":"2016-08-24","completion":"2020-06-27","firstPosted":"2013-11-21","resultsPosted":"2018-01-23","lastUpdate":"2021-07-06"},"enrollment":707,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Breast Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"PF-05280014","otherNames":["Trastuzumab-Pfizer"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"BIOLOGICAL","name":"Herceptin速","otherNames":["Trastuzumab (EU)"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"PF-05280014","type":"EXPERIMENTAL"},{"label":"Herceptin速","type":"ACTIVE_COMPARATOR"}],"summary":"The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-05280014 in combination with paclitaxel versus trastuzumab sourced from the European Union (trastuzumab-EU) with paclitaxel in female patients with HER2-positive, metastatic breast cancer in the first-line treatment setting. The hypothesis to be tested in this study is that the efficacy (ORR) of PF-05280014 is similar to trastuzumab-EU.","primaryOutcome":{"measure":"Objective Response Rate (ORR) Derived From Central Radiology Assessments: ITT Population","timeFrame":"From the date of randomization until all participants had either completed the Week 33 tumor assessment or discontinued study drug earlier than the Week 33 visit","effectByArm":[{"arm":"PF-05280014","deltaMin":62.5,"sd":null},{"arm":"Trastuzumab-EU","deltaMin":66.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":188,"countries":["United States","Argentina","Brazil","Chile","Czechia","Greece","Hungary","India","Japan","Latvia","Mexico","Peru","Philippines","Poland","Portugal","Romania","Russia","Serbia","Slovakia","South Africa","South Korea","Thailand","Turkey (T端rkiye)","Ukraine"]},"refs":{"pmids":["35133617","31053945","30568294"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3271002&StudyName=A%20Phase%203%20Randomized%2C%20Double-blind%20Study%20Of%20Pf-05280014%20Plus%20Paclitaxel%20Versus%20Trastuzumab%20Plus%20Paclitaxel%20For%20The%20First-line%20Treatment%20Of%20Patients%20With%20Her2-positive%20Metastatic%20Breast%20Cancer"]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":349},"commonTop":["Alopecia","Anaemia","Neutropenia","Peripheral sensory neuropathy","Nausea"]}}